{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:04:18Z","timestamp":1792843458908,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UAB Center for Addiction and Pain Prevention and Intervention"},{"name":"UAB Addiction, Infection, and Immunology Research Program"},{"name":"Agency for Healthcare Research and Quality, United States","award":["T32HS013852"],"award-info":[{"award-number":["T32HS013852"]}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["T32HS013852"],"award-info":[{"award-number":["T32HS013852"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"crossref","award":["T32DA013911"],"award-info":[{"award-number":["T32DA013911"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000074","name":"U.S. Department of Justice","doi-asserted-by":"crossref","award":["15NIJ-24-GK-00981-COAP"],"award-info":[{"award-number":["15NIJ-24-GK-00981-COAP"]}],"id":[{"id":"10.13039\/100000074","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Alabama, like other states in the Deep South, lacks comprehensive testing for novel psychoactive substances (NPS) and adulterants like xylazine, leaving gaps in the detection of drug supply changes. From August 2024 to July 2025, we implemented an active testing approach at an emergency department (ED) in central Alabama among people with active illicit fentanyl use. Testing residual biological specimens collected as part of health care offers a potentially useful window into the prevalence of NPS in the drug supply, particularly in communities where traditional drug checking services might be impermissible or difficult to resource. In this study, we used liquid chromatography-quadrupole time of flight mass spectrometry (LC-QTOF-MS) to test the participants\u2019 residual biological specimens (blood, urine) coupled with a survey focused on demographics and drug use. We enrolled 37 participants who completed surveys, and 31 who completed LC-QTOF-MS testing. 84% of participants were white (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931), 51.4% were male (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919), 54.1% were homeless (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920), and 45.9% resided in rural areas (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200917). In participants with comprehensive toxicology testing (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931, 83.8%), we detected xylazine in 25 (80.6%). We identified the first confirmed case of medetomidine exposure in the state of Alabama. We also identified a high proportion of samples with the NPS\n                    <jats:italic>o<\/jats:italic>\n                    -methylfentanyl (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20099, 29.0%), the first published identification of this substance in the region to our knowledge. Among participants with toxicology testing, 59.3% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200916) had previously heard of xylazine and 41.9% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200913) had knowingly used it in the past. This pilot study demonstrated the feasibility and practical utility of ED-based residual biological specimen illicit drug surveillance. This approach has the potential to identify new emerging substances in the unregulated drug supply.\n                  <\/jats:p>","DOI":"10.1186\/s12954-026-01401-5","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T15:04:24Z","timestamp":1768662264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emergency department-based testing for xylazine and other novel psychoactive substances in Central Alabama: a feasibility study"],"prefix":"10.1186","volume":"23","author":[{"given":"William","family":"Bradford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"Bratches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Figgatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goodman-Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kertesz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"1401_CR1","unstructured":"UNODC. World drug report 2024. Volume 35. United Nations office on drugs and crime; 2024. pp. 35."},{"key":"1401_CR2","doi-asserted-by":"publisher","first-page":"109380","DOI":"10.1016\/j.drugalcdep.2022.109380","volume":"233","author":"J Friedman","year":"2022","unstructured":"Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, Shover C. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380.","journal-title":"Drug Alcohol Depend"},{"key":"1401_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12954-024-00940-z","volume":"21","author":"D German","year":"2024","unstructured":"German D, Genberg B, Sugarman O, Saloner B, Sawyer A, Glick JL, Gribbin M, Flynn C. Reported xylazine exposure highly associated with overdose outcomes in a rapid community assessment among people who inject drugs in Baltimore. Harm Reduct J. 2024;21:18.","journal-title":"Harm Reduct J"},{"key":"1401_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.15585\/mmwr.mm7326a2","volume":"73","author":"X Jiang","year":"2024","unstructured":"Jiang X, Connolly S, Strahan AE, Rivera Blanco L, Mikosz CA, Guy GP, Dowell D. Reported xylazine use among adults aged\u2009\u2265\u200918 years evaluated for substance use treatment\u2014United States, July 2022\u2013September 2023. MMWR Morb Mortal Wkly Rep. 2024;73:594\u20139.","journal-title":"MMWR Morbidity Mortal Wkly Rep"},{"key":"1401_CR5","doi-asserted-by":"crossref","unstructured":"Kariisa M, O\u2019Donnell J, Kumar S, Mattson CL, Goldberger BA. Illicitly manufactured Fentanyl\u2013Involved overdose deaths with detected xylazine\u2014United States, January 2019\u2013June 2022. Morbidity and mortality weekly report. Centers for Diseaese Control and Prevention; 2023. pp. 721\u20137.","DOI":"10.15585\/mmwr.mm7226a4"},{"key":"1401_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/15271544241268386","volume":"25","author":"EF Kyei","year":"2024","unstructured":"Kyei EF, Kyei GK, Ansong R, Boakye CK, Asamoah E. Xylazine in the unregulated drug market: an integrative review of its prevalence, health impacts, and detection and intervention challenges in the united States. Policy Politics Nurs Pract. 2024;25:241\u201353.","journal-title":"Policy Politics Nurs Pract"},{"key":"1401_CR7","doi-asserted-by":"publisher","first-page":"104154","DOI":"10.1016\/j.drugpo.2023.104154","volume":"120","author":"T Quijano","year":"2023","unstructured":"Quijano T, Crowell J, Eggert K, Clark K, Alexander M, Grau L, Heimer R. Xylazine in the drug supply: emerging threats and lessons learned in areas with high levels of adulteration. Int J Drug Policy. 2023;120:104154.","journal-title":"Int J Drug Policy"},{"key":"1401_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12954-025-01237-5","volume":"22","author":"LAD Gomez","year":"2025","unstructured":"Gomez LAD, Estrada Y, Sauer J, Zaidi I, Trinidad AJ, Helmy H, Harocopos A. Community-based drug checking at syringe service programs in new York City observe an increasing prevalence of xylazine from 2021 through 2024. Harm Reduct J. 2025;22:99.","journal-title":"Harm Reduct J"},{"key":"1401_CR9","unstructured":"Cdc. Understanding the opioid overdose epidemic. Overdose Prevention; 2025."},{"key":"1401_CR10","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/add.16318","volume":"118","author":"J Friedman","year":"2023","unstructured":"Friedman J, Shover CL. Charting the fourth wave: geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010\u20132021. Addiction. 2023;118:2477\u201385.","journal-title":"Addiction"},{"key":"1401_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/15563650.2022.2159427","volume":"61","author":"JS Love","year":"2023","unstructured":"Love JS, Levine M, Aldy K, Brent J, Krotulski AJ, Logan BK, Vargas-Torres C, Walton SE, Amaducci A, Calello D, et al. Opioid overdoses involving xylazine in emergency department patients: a multicenter study. Clin Toxicol. 2023;61:173\u201380.","journal-title":"Clin Toxicol"},{"key":"1401_CR12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","volume":"112","author":"RS Alexander","year":"2022","unstructured":"Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112:1212\u20136.","journal-title":"Am J Public Health"},{"key":"1401_CR13","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","volume":"240","author":"S Choi","year":"2023","unstructured":"Choi S, Irwin MR, Kiyatkin EA. Xylazine effects on opioid-induced brain hypoxia. Psychopharmacology. 2023;240:1561\u201371.","journal-title":"Psychopharmacology"},{"key":"1401_CR14","doi-asserted-by":"publisher","first-page":"104338","DOI":"10.1016\/j.drugpo.2024.104338","volume":"125","author":"JM Bowles","year":"2024","unstructured":"Bowles JM, Copulsky EC, Reed MK. Media framing xylazine as a zombie drug is amplifying stigma onto people who use drugs. Int J Drug Policy. 2024;125:104338.","journal-title":"Int J Drug Policy"},{"key":"1401_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","volume":"240","author":"K Ruiz-Col\u00f3n","year":"2014","unstructured":"Ruiz-Col\u00f3n K, Chavez-Arias C, D\u00edaz-Alcal\u00e1 JE, Mart\u00ednez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1\u20138.","journal-title":"Forensic Sci Int"},{"key":"1401_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/29767342231214472","volume":"45","author":"JJ Carroll","year":"2024","unstructured":"Carroll JJ. Xylazine-Associated wounds and related health concerns among people who use drugs: reports from front-line health workers in 7 US States. Subst Use Addict J. 2024;45:222\u201331.","journal-title":"Subst Use Addict J"},{"key":"1401_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/ADM.0000000000001383","volume":"19","author":"O Heidari","year":"2025","unstructured":"Heidari O, Sugarman OK, Winiker AK, Gattine S, Flanagan V, Razaghi R, Saloner BK. Personal experiences with xylazine and behavior change: a qualitative content analysis of reddit posts. J Addict Med. 2025;19:135\u201342.","journal-title":"J Addict Med"},{"key":"1401_CR18","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.7326\/M23-2001","volume":"176","author":"J D\u2019Orazio","year":"2023","unstructured":"D\u2019Orazio J, Nelson L, Perrone J, Wightman R, Haroz R. Xylazine adulteration of the Heroin\u2013Fentanyl drug supply: a narrative review. Ann Intern Med. 2023;176:1370\u20136.","journal-title":"Ann Intern Med"},{"key":"1401_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.70051","author":"P Owusu-Antwi","year":"2025","unstructured":"Owusu-Antwi P, Atodaria P, Appiah\u2010Kubi E, Shah Z, Garcia EM. Management of xylazine toxicity, overdose, dependence, and withdrawal: a systematic review. Am J Addictions. 2025. https:\/\/doi.org\/10.1111\/ajad.70051","journal-title":"Am J Addictions"},{"key":"1401_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12954-024-01082-y","volume":"21","author":"WH Eger","year":"2024","unstructured":"Eger WH, Plesons M, Bartholomew TS, Bazzi AR, Hauschild MH, McElrath CC, Owens C, Forrest DW, Tookes HE, Crable EL. Syringe services program staff and participant perspectives on changing drug consumption behaviors in response to xylazine adulteration. Harm Reduct J. 2024;21:162.","journal-title":"Harm Reduct J"},{"key":"1401_CR21","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.dadr.2022.100074","volume":"4","author":"MK Reed","year":"2022","unstructured":"Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL. Perspectives of people in Philadelphia who use fentanyl\/heroin adulterated with the animal tranquilizer xylazine; making a case for xylazine test strips. Drug Alcohol Depend Rep. 2022;4:100074.","journal-title":"Drug Alcohol Depend Rep"},{"key":"1401_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11916-024-01211-z","volume":"28","author":"AN Edinoff","year":"2024","unstructured":"Edinoff AN, Sall S, Upshaw WC, Spillers NJ, Vincik LY, De Witt AS, Murnane KS, Kaye AM, Kaye AD. Xylazine: a drug adulterant of clinical concern. Curr Pain Headache Rep. 2024;28:417\u201326.","journal-title":"Curr Pain Headache Rep"},{"key":"1401_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12954-023-00879-7","volume":"20","author":"CM Zagorski","year":"2023","unstructured":"Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, Stahl NE, Hill LG, McElligott Z, Dasgupta N. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20:141.","journal-title":"Harm Reduct J"},{"key":"1401_CR24","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15585\/mmwr.mm7217a2","volume":"72","author":"E Russell","year":"2023","unstructured":"Russell E, Sisco E, Thomson A, Lopes J, Rybak M, Burnett M, Heilman D, Appley MG, Gladden RM. Rapid analysis of drugs: a pilot surveillance system to detect changes in the illicit drug supply to guide timely harm reduction responses\u2014eight syringe services programs, Maryland, November 2021\u2013August 2022. MMWR Morb Mortal Wkly Rep. 2023;72:458\u201362.","journal-title":"MMWR Morbidity Mortal Wkly Rep"},{"key":"1401_CR25","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1177\/0033354920921817","volume":"135","author":"MH Fern\u00e1ndez-Vi\u00f1a","year":"2020","unstructured":"Fern\u00e1ndez-Vi\u00f1a MH, Prood NE, Herpolsheimer A, Waimberg J, Burris S. State laws governing syringe services programs and participant syringe possession, 2014\u20132019. Public Health Reports\u00ae. 2020;135:S128\u201337.","journal-title":"Public Health Reports\u00ae"},{"key":"1401_CR26","unstructured":"Cdc. About the state unintentional drug overdose reporting system (SUDORS). Overdose Prevention; 2025."},{"key":"1401_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/00952990.2022.2072223","volume":"48","author":"A Denham","year":"2022","unstructured":"Denham A, Vasu T, Avendano P, Boslett A, Mendoza M, Hill EL. Coroner County systems are associated with a higher likelihood of unclassified drug overdoses compared to medical examiner county systems. Am J Drug Alcohol Abuse. 2022;48:606\u201317.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1401_CR28","unstructured":"Centers for Disease C. Prevention: state medical examiners and coroners organizations; 2024."},{"key":"1401_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12954-024-00959-2","volume":"21","author":"W Bradford","year":"2024","unstructured":"Bradford W, Figgatt M, Scott KS, Marshall S, Eaton EF, Dye DW. Xylazine co-occurrence with illicit Fentanyl is a growing threat in the deep south: a retrospective study of decedent data. Harm Reduct J. 2024;21:46.","journal-title":"Harm Reduct J"},{"key":"1401_CR30","doi-asserted-by":"publisher","first-page":"112763","DOI":"10.1016\/j.drugalcdep.2025.112763","volume":"274","author":"K Hochstatter","year":"2025","unstructured":"Hochstatter K, Nadel T, Sisco E, Bourgois P, Laurel S, Appley MG, Pyfrom EM, Montero F. Characterizing rapid changes in the prevalence and concentration of key compounds in philadelphia\u2019s street opioid retail supply, March 2024-March 2025. Drug Alcohol Depend. 2025;274:112763.","journal-title":"Drug Alcohol Depend"},{"key":"1401_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/YCO.0000000000000938","volume":"37","author":"ND Fitzgerald","year":"2024","unstructured":"Fitzgerald ND, Cottler LB, Palamar JJ. Public health surveillance of new psychoactive substances: recent developments. Curr Opin Psychiatry. 2024;37:270\u20136.","journal-title":"Curr Opin Psychiatry"},{"key":"1401_CR32","doi-asserted-by":"publisher","first-page":"109195","DOI":"10.1016\/j.drugalcdep.2021.109195","volume":"230","author":"BE Schwartz","year":"2022","unstructured":"Schwartz BE, Dezman Z, Billing AS, Heine K, Massey E, Artigiani EE, Motavalli M, Burch G, Gandhi P, Wish ED. Emergency department drug surveillance (EDDS) hospital\u2019s Urinalysis results compared with expanded re-testing by an independent laboratory, a pilot study. Drug Alcohol Depend. 2022;230:109195.","journal-title":"Drug Alcohol Depend"},{"key":"1401_CR33","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"key":"1401_CR34","unstructured":"National Center for, Education S, Education, USDo, Institute of Education S. NCES EDGE geographic locale boundaries. In: Demographic NE, Geographic Estimates P, editors. Washington, DC: National Center for Education Statistics (NCES); 2024."},{"key":"1401_CR35","doi-asserted-by":"publisher","first-page":"100193","DOI":"10.1016\/j.dadr.2023.100193","volume":"9","author":"OK Golan","year":"2023","unstructured":"Golan OK, Sheng F, Dick AW, Sorbero M, Whitaker DJ, Andraka-Christou B, Pigott T, Gordon AJ, Stein BD. Differences in medicaid expansion effects on buprenorphine treatment utilization by County rurality and income: a pharmacy data claims analysis from 2009\u20132018. Drug Alcohol Depend Rep. 2023;9:100193.","journal-title":"Drug Alcohol Depend Rep"},{"key":"1401_CR36","doi-asserted-by":"publisher","first-page":"104805","DOI":"10.1016\/j.drugpo.2025.104805","volume":"140","author":"AM Morenz","year":"2025","unstructured":"Morenz AM, Nance RM, Mixson LS, Feinberg J, Smith G, Korthuis PT, Pho MT, Jenkins WD, Friedmann PD, Stopka TJ, et al. Barriers to accessing medications for opioid use disorder among rural individuals. Int J Drug Policy. 2025;140:104805.","journal-title":"Int J Drug Policy"},{"key":"1401_CR37","unstructured":"Stang BN, Walton SE, Merette S, Shaprio A, Papsun DM, Peterson B, Logan BK, Krotulski AJ. Ortho-methylfentanyl proliferating across North America as newest synthetic opioid identified in fatal drug overdoses. Center for Forensic Science Research and Education; 2024."},{"key":"1401_CR38","unstructured":"Krotulski AJ, Shinfeld J, Moraff C, Wood T, Walton SE, DeBord JS, Denn MT, Quinter AD, Logan BK. Medetomidine rapidly proliferating across USA\u2014implicated. Recreational opioid drug supply & causing overdose outbreaks. Center for Forensic Science Research and Education; 2024."},{"key":"1401_CR39","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1080\/09540121.2012.663886","volume":"24","author":"MM Islam","year":"2012","unstructured":"Islam MM, Topp L, Conigrave KM, van Beek I, Maher L, White A, Rodgers C, Day CA. The reliability of sensitive information provided by injecting drug users in a clinical setting: clinician-administered versus audio computer-assisted self-interviewing (ACASI). AIDS Care. 2012;24:1496\u2013503.","journal-title":"AIDS Care"},{"key":"1401_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","volume":"46","author":"JJ Lister","year":"2020","unstructured":"Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46:273\u201388.","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01401-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:51:15Z","timestamp":1770835875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01401-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1401"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01401-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the IRB (IRB-300012605).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}